FDA Approves Enbrel Autoinjector
Useful for patients with psoriatic and rheumatic diseases who have difficulty with or are unwilling to administer injections
THURSDAY, June 22 (HealthDay News) -- The U.S. Food and Drug Administration has approved the Enbrel (etanercept) SureClick autoinjector as the first and only autoinjector for psoriatic and rheumatic diseases, according to Amgen, the manufacturer.
The single-use autoinjector comes prefilled with a 50 mg/mL dose of Enbrel and contains three safety features. According to Amgen, patients never see the needle.
Amgen notes that the autoinjector provides another option to patients who may have difficulty with or are unwilling to administer injections.
Enbrel is approved to treat plaque psoriasis, psoriatic arthritis, juvenile and adult rheumatoid arthritis and ankylosing spondylitis. Amgen notes that there are now three administration options for Enbrel: the 50 mg/mL prefilled syringe, the 25 mg multiple-use vial, and the SureClick autoinjector.
The Enbrel SureClick autoinjector should be available this summer, the company notes.